Register
Login

Trending Topic

abstract blue eye
8 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

On 28 May 2024, enrolment in phase III clinical trials for sozinibercept in neovascular age-related macular degeneration (nAMD) was completed.1 These trials include two large multicentre, double-masked, randomized controlled trials (RCTs): COAST (OPT-302 with aflibercept in neovascular age-related macular degeneration; ClinicalTrials.gov identifier: NCT04757636) and ShORe (OPT-302 with ranibizumab in neovascular age-related macular degeneration; ClinicalTrials.gov identifier: NCT04757610).2,3 These trials represent one of the largest phase […]

Noel Alpins, ESCRS 2018 – Overview of Astigmatism Laser Surgery

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Published Online: Oct 16th 2018
 

We caught up with Dr Noel Alpins at ESCRS 2018 to discuss astigmatism surgery. In this first video he discusses the advantages and disadvantages of wearing spectacles or glasses, and how these disadvantages can be overcome with astigmatism laser surgery. He also describes which patients would be suitable for the surgery.

Questions:
Part 1:
1. Which treatment options are available for astigmatism? Are spectacles enough to correct vision, or are other treatments such as surgery sometimes needed? (0:08)
2. How do you identify patients most suitable for astigmatism surgery, as well as patients with astigmatism for which surgery is not recommended? (1:40)
Part 2:
1. Which are the main challenges and pitfalls associated with astigmatism surgery? Are they avoidable and predictable? (0:08)
2. What further studies are planned to help overcome these challenges? (1:03)

Speaker disclosures: Dr Noel Alpins would like to disclose his association with ASSORT Surgical Management Systems.

Filmed at the 36th Congress of the European Society of Cataract & Refractive Surgeons (ESCRS), Vienna, Austria, 22–26 September 2018

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Close Popup